Parabon NanoLabs is a pioneering brand in the field of DNA technology, offering a range of innovative products and services. As a vertically integrated company, Parabon leverages the power of DNA to develop next-generation therapeutic and forensic solutions. With a team of highly qualified scientists and technologists, Parabon utilizes expertise in bioinformatics, immunology, chemistry, and computer science to create revolutionary products.

Their breakthroughs have been made possible by advancements in DNA sequencing, analysis, and manufacturing technologies. While Parabon primarily focuses on technologies for the medical industry, they have gained widespread recognition for revolutionizing DNA forensics with their Snapshot® Advanced DNA Analysis Platform. Their excellence in technology innovation has been recognized with the prestigious Tibbetts Award from the Small Business Administration (SBA) and being named one of the Top 5 Most Innovative Companies of 2018 by Inc.

Magazine. Parabon NanoLabs' foundation was established in 2005 by Dr. Michael Norton and Dr.

Steven Armentrout, with the mission to create breakthrough products using DNA. Over the years, they have expanded their applications to include oncology therapeutics, synthetic vaccines, forensic DNA analysis, and determining genetic predisposition to specific diseases. With a highly experienced management and scientific team led by Dr.

Steven Armentrout as Co-Founder and CEO, Dr. Michael L. Norton as Co-Founder and Chief Science Officer, and Principal Investigators like Dr.

Ellen McRae Greytak, Dr. David Danley, and CeCe Moore, Parabon NanoLabs is at the forefront of DNA technology research and development. By pushing the boundaries of DNA technology, Parabon NanoLabs is shaping the future of therapeutic and forensic solutions, driving advancements that have the potential to transform healthcare and law enforcement